The study involved 153 patients with posterior segment uveitis and the primary endpoint was prevention of recurrence of posterior uveitis
at six months with patients continuing to be followed for 36 months.
Toxoplasmosis accounted for 43% of symptomatic cases of posterior uveitis
in 1 study (27), and it was probably a common cause among the patients in our study, although no serologic testing for toxoplasmosis was available.
NICE concluded that Ozurdex is a cost and clinically-effective treatment option used in the treatment of sight-threatening posterior non-infectious posterior uveitis
BS patients without p-NBS were then sub-grouped according to their type of involvement such as mucocutaneous, posterior uveitis
, and vascular involvement group.
Toxoplasmic retinochoroiditis (TR) is the most common identifiable cause of posterior uveitis
Clinical aspects of posterior uveitis
in ocular sarcoidosis.
For the purpose of the study, the researchers assigned 217 adults - with active, non-infectious intermediate or posterior uveitis
- to a group that received either adalimumab or a placebo at the beginning of the trial, continuing with a dose every two weeks after that.
pSivida's lead product candidate, Medidur, a micro-insert for posterior uveitis
being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017.
Global Markets Direct's, 'Posterior Uveitis
- Pipeline Review, H1 2016', provides an overview of the Posterior Uveitis
Biologic therapy for posterior uveitis
This classification includes anterior uveitis, intermediate uveitis, posterior uveitis
, and panuveitis.
Non-infectious intermediate and posterior uveitis
(NIU) represents 10%-15% of uveitis cases, and is the 4th cause of blindness, affects about 250,000 patients in North America and Europe.